The Serine and Arginine Rich Splicing Factor 2 (SRSF2) is a splicing factor in which mutations occur in up to 20% of AML/MDS and is frequently associated with mtRUNX1, conferring a particularly poor prognosis [24]. This evidence concerns the gene SRSF2 and acute myeloid leukemia.